Treatment of cancer by an inducer of reverse transformation.
Thiazolidine-4-carboxylic acid (thioproline, "norgamem") a compound found to act on the cell membrane of tumour cells, causing reverse transformation to normal cells was investigated in patients with advanced cancer. Responses were obtained at several dose levels mainly in epidermoid carcinoma of the head and neck with pulmonary metastases. Histological studies showed involution and transformation into low-grade malignancies and disappearance of evidence of cancer.
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002264:Carboxylic Acids / Q000008:administration & dosage; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D002471:Cell Transformation, Neoplastic / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004338:Drug Combinations; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy; D006801:Humans; D007263:Infusions, Parenteral; D007273:Injections, Intramuscular; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology; D013844:Thiazoles / Q000008:administration & dosage*; D053778:Thiazolidines
D000970:Antineoplastic Agents; D002264:Carboxylic Acids; D004338:Drug Combinations; D013844:Thiazoles; D053778:Thiazolidines; C003438:thiazolidine-4-carboxylic acid